Related Experiment Video
Updated: May 1, 2026
06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
37.8K
[Myoclonus in Alzheimer's disease]
A N Bogolepova1,2, S G Burd1,2, A V Lebedeva1,2
1Federal Center for Brain and Neurotechnologies of the Federal Medical Biological Agency of Russia, Moscow, Russia.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|April 29, 2026
Summary
Myoclonus, involuntary muscle twitches, affects up to 50% of early-onset Alzheimer's disease (AD) patients. Early diagnosis and video-EEG monitoring are crucial for managing this symptom and its potential link to seizures.
Area of Science:
- Neurology
- Neuroscience
Background:
- Myoclonus, characterized by sudden, involuntary muscle contractions, is a common symptom in neurodegenerative diseases.
- In Alzheimer's disease (AD), myoclonus can manifest in up to 50% of early-onset and atypical cases.
- Epileptic myoclonus may signal an increased risk of seizures and accelerated cognitive decline.
Purpose of the Study:
- To describe the key features of myoclonus in Alzheimer's disease.
- To explore the utility of diagnostic tools, such as video-electroencephalographic (video-EEG) monitoring, for differentiating myoclonus types in AD.
- To present a clinical case illustrating both epileptic and non-epileptic myoclonus in an AD patient.
Main Methods:
- Literature review on myoclonus in Alzheimer's disease.
- Discussion of diagnostic approaches, including video-EEG monitoring.
- Presentation of a detailed clinical case study.
Main Results:
- Myoclonus is a significant clinical feature in a substantial proportion of Alzheimer's disease patients, particularly those with early-onset or atypical presentations.
- Video-EEG monitoring is a valuable tool for the differential diagnosis and etiological clarification of myoclonus in AD.
- The clinical case highlights the coexistence and diagnostic challenges of epileptic and non-epileptic myoclonus in AD.
Conclusions:
- Accurate diagnosis of myoclonus in AD is essential for appropriate treatment and improved patient quality of life.
- Integrating advanced diagnostic methods like video-EEG can enhance the management of myoclonus in AD.
- Understanding the nuances of myoclonus, including its epileptic or non-epileptic nature, is critical for predicting disease progression and guiding therapeutic strategies.
Keywords:
Alzheimer’s diseaseelectromyographyepileptiform activitymyoclonusneurodegenerative diseasesomatosensory evoked potentialsvideo EEG monitoringMore Related Videos
Related Concept Videos
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:11Alterations in Muscle Tone lll
29
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
29
01:12Alterations in Muscle Tone ll
27
Alterations in muscle tone are common manifestations of neurological disorders and reflect dysfunction within different nervous system regions. Spasticity, paratonia, and dystonia represent distinct forms of hypertonia, each with unique mechanisms, clinical features, and diagnostic importance.CharacteristicsSpasticity happens from upper motor neuron lesions and is characterized by velocity-dependent resistance to passive movement. Clinical features include:Exaggerated deep tendon reflexesClonus...
27